Synlogic

As Synlogic continues to evaluate strategic options, we salute all Synlogicians who have been part of our journey. As always, our leader Aoife Brennan found the right words: “We all took on a big challenge – to develop a new treatment modality – and to do something nobody had done before.” And most importantly, to provide a new class of medicines with the potential to transform care, improving lives of patients in need. Along the way, we created a special place to work, where people could thrive, grow and enjoy their days while advancing science. Our resume book has gone out for those Synlogicians who are now moving into their next chapters, but if you missed it and would like to receive it please contact Adam Thomas (he/him) at adamHR@synlogictx.com.  

Thank you Adam Thomas (he/him) for these terrific hybrid work acronyms from across the pond! Reminder to Everyone Else: the Synlogic Resume Book will be out shortly - please contact Adam to learn about the amazing Synlogicians seeking a new chapter.

We appreciate and share this thoughtful reflection from the one and only Adam Thomas (he/him), our #chiefpeopleofficer, who shaped and lived the special culture that made Synlogic. Thanks Adam!!

Thank You CanPKU+ !! This means a great deal to all Synlogicians, past and present.

Yesterday we announced the decision to end Synpheny-3, our pivotal study in phenylketonuria (PKU), and that as a result, Synlogic will be evaluating strategic options for the company and ceasing operations (see below press release). We express our sincere appreciation to everyone who has worked for and with Synlogic, as we have advanced science, while building a special company and place to work. We extend particular gratitude to the PKU & HCU communities, who inspired us, and whose partnership enabled our pursuit of a shared aspiration to bring forward a meaningful new class of medicines. For more information, please read: https://loom.ly/FZtxgso

Congratulations to the authors! Proud to see this manuscript summarizing the journey of SYNB1353, our drug candidate for classical #HCU, published in Cell Host & Microbe: https://loom.ly/dU6m0Mg @CellPressNews #inbornerrors #homocystinuria #rarediseases #synbio #syntheticbiology

Congratulations to Makswell Vittands on his 5th Year Anniversary as a Synlogician! Thank you for your remarkable and many contributions!

What a year for our #regulatory rockstars. In just one year, SYNB1934 received Rare Pediatric Disease, Fast Track, and Orphan designations from the FDA, Orphan designation from the EMA, AND WHO's go-ahead for our non-proprietary name: labafenogene marselecobac! Learn about these accomplishments and more: https://loom.ly/r2HF30k

To those of you who work in #newbornscreening, I’m sharing this from a friend of mine, Kala McWain. She’s a parent of a child with PKU, and we serve together in various advocacy projects on social media and for the National PKU Alliance. Please take a moment to read one family’s experience receiving a PKU diagnosis: “I share this every year because the way in which these positive newborn screening results are delivered to families is wrong. At least in our experience, it could have and SHOULD HAVE gone better. The call went something like this: “This is Stephanie the nurse from Dr. Taylor’s office. He is on call for Braxton’s pediatrician and we just had some results to share with you. We don’t know too much at this time, but his newborn screening came back positive for PKU and a thyroid dysfunction. We get false positives all the time, so we just need you to return to the lab today for more blood work. We don’t recommend Googling it, and we will call you with the results.” *names have been changed because names didn’t really matter at that point. We waited the whole weekend for a call from SOMEONE, anyone! …and yeah, we did Google it because no one told us ANYTHING! They left two parents in the dark, because they weren’t education enough on what a diagnosis of PKU meant. Google told us a lot, a lot of scary stuff, a lot of damaging stuff. Google didn’t tell us the good stuff, that a treatment was available, and the positive outcomes from that treatment. That follow up call came 3 days after the call where we were given false hope that this could be a false positive. Braxton was still positive for PKU, but no longer positive for a thyroid dysfunction. So, sure, a false positive can happen but it was a less than helpful choice in words. I think the call should have come from Braxton’s provider, or at the least the provider on call. Not a nurse that could do little to reassure me because she received no education on this in nursing school. Better yet, a follow up call from the on call Genetics & Metabolic’s department - just to give us SOMETHING. The sad part is we are not the only ones with a story like this, and I welcome you to share your story in the comments. We are entirely grateful for Newborn Screening for saving Braxton’s life, but I think the delivery of positive results could be improved upon. After all, a disease doesn’t make it on the newborn screening panel unless there is a treatment or positive outcome involved.” I’ll just say this… The news that people receive matters. But HOW they receive it also matters. Because I guarantee you… Families remember these phone calls for the rest of their lives.

3 major milestones in the next 18 months for our #Phase3 study in PKU. Learn more here: https://loom.ly/zN5Vods $SYBX #SYBX #biotechstocks #investmentideas #catalysts #raredisase